New Delhi, April 16 -- India's pharmaceutical industry has urged the Drug Controller General of India (DCGI) to relax newly introduced export guidelines, citing concerns over a potential USD 3 billion loss in annual export revenues.

As per sources, the revised rules-effective from March 7, 2025-mandate that companies obtain prior regulatory approval from the importing country before applying for a No Objection Certificate (NOC) from the DCGI. Without the NOC, no pharmaceutical exports can proceed.

Industry representatives argue that these norms are proving to be a roadblock for ongoing and future export contracts.

"Many nations like Yemen, Ghana, and Rwanda lack the regulatory systems needed to issue such approvals," sources told CNBC-...